Indocyanine green and Eylea drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Indocyanine green (indocyanine green) and Eylea (aflibercept). Common drug interactions include visual acuity reduced among males.

The phase IV clinical study analyzes what interactions people have when they take Indocyanine green and Eylea. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Indocyanine green?

Indocyanine green has active ingredients of indocyanine green. eHealthMe is studying from 122 Indocyanine green users. Check the latest studies of Indocyanine green.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

On Jul, 17, 2026

12 people who take Indocyanine green and Eylea together, and have interactions are studied.

Indocyanine green and Eylea drug interactions.

What are the common drug interactions of Indocyanine Green and Eylea, by gender? *:

female:

n/a

male:

Visual acuity reduced (reduced clearness of vision)
Age-related macular degeneration
Retinal haemorrhage (bleeding from retina)
Vitreous haemorrhage (intraocular (inside the eye) bleeding)
Drug resistance (reduction in effectiveness of a drug)
Retinal exudates (discharge from retina)
Retinal vascular disorder (a range of eye diseases that affect the blood vessels in the eye)
Cataract (clouding of the lens inside the eye)
Contrast media allergy (reaction associated with the use of intravenous contrast material during radiology)
Retinal scar (development of scar tissue on retina)

What are the common drug interactions of Indocyanine Green and Eylea, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Visual acuity reduced (reduced clearness of vision)
Age-related macular degeneration
Retinal haemorrhage (bleeding from retina)
Vitreous haemorrhage (intraocular (inside the eye) bleeding)
Drug resistance (reduction in effectiveness of a drug)
Retinal exudates (discharge from retina)
Retinal vascular disorder (a range of eye diseases that affect the blood vessels in the eye)
Cataract (clouding of the lens inside the eye)
Contrast media allergy (reaction associated with the use of intravenous contrast material during radiology)
Retinal scar (development of scar tissue on retina)

What are the existing conditions these people have? *

Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 8 people, 66.67%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 4 people, 33.33%
Age-Related Macular Degeneration: 3 people, 25.00%
Pain: 2 people, 16.67%
High Blood Pressure: 2 people, 16.67%
Sleep Apnea Syndrome: 1 person, 8.33%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 1 person, 8.33%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 8.33%
Gastric Ulcer (stomach ulcer): 1 person, 8.33%
Dyslipidaemia (abnormal amount of lipids): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Indocyanine green and Eylea?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously